Physician profile
John P Preece
NPI 1750723110
$737.25
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.78 · 2020: $192 · 2021: $249 · 2022: $143 · 2023: $63.92 · 2024: $46.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $167.32 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $142.68 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $92.27 | 2020-2021 | |
| Abbvie INC. | $60.35 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $41.84 | 2021 | |
| Merck Sharp & Dohme LLC | $40.32 | 2019-2023 | |
| Daxor Corporation | $39.92 | 2023 | Bva-100 |
| La Jolla Pharmaceutical Company | $37.54 | 2021 | |
| Edwards Lifesciences Corporation | $29.20 | 2020-2021 | |
| Allergan, INC. | $26.38 | 2019-2020 | |
| Akcea Therapeutics, INC. | $18.94 | 2020 | |
| Fisher & Paykel Healthcare INC | $14.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.28 | 2021 | |
| Chiesi USA, INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Preece listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.